Upharmacia August 2017 | Page 6

Upharmacia August 2017 PHARMA MARKET NEWS I nterchem L ocalized M anufacturing in K azakhstan Ukrainian company Interchem reached agreement on localization of manufacturing of its three drugs at the facilities of Kazakh company Viva Pharm in Almaty. The plant will produce antiviral drug Tilaxin (tilorone), anxiolytic Gidazepam VIC (hydazepam) and opioid analgesic Morphine sulfate VIC (morphine). Medical director of Viva Pharm stated that the companies striving to localize another range of drugs. The cooperation was stimulated through government policy to support local manufacturing providing that the transfer of production technologies in Kazakhstan is more profitable than the import of finished medicines. “Kazakhstan’s pharmaceutical market is developing dynamically,” Deputy GM of Interchem said. “Considering state policy of Kazakhstan on stimulation of local pharmaceutical production, we decided to arrange the manufacturing of demanded drugs there. We have found the partner, which we sure would ensure a consistently high quality of products.” Moreover, in Aug, Interchem entered the sports nutrition market with three products: BCAA, creatine, L-carnitine. All products are presented under the name SMARTPIT®. In 2016, Interchem was 25th company on Ukrainian retail drug market by sales. 6 A cino W ill R epresent 9 M edicines of M erck in CIS and M oldova Swizz company Acino reached distribution agreement with Merck to represent 9 medicines against cardiovascular and endocrine diseases. Since Jan 1, 2018, these drugs will be available in Ukraine, Armenia, Azerbaijan, K